I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
PCN supported the use of bevacizumab as a second line treatment option for patients with non-infectious sight threatening or sight-losing intermediate or posterior uveitis who are unable to receive intravitreal dexamethasone (Ozurdex) due to a contraindication.
